These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26115634)

  • 1. Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.
    McCormack PL
    BioDrugs; 2015 Jun; 29(3):207-14. PubMed ID: 26115634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
    Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
    Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
    Robak T; Huang H; Jin J; Zhu J; Liu T; Samoilova O; Pylypenko H; Verhoef G; Siritanaratkul N; Osmanov E; Alexeeva J; Pereira J; Drach J; Mayer J; Hong X; Okamoto R; Pei L; Rooney B; van de Velde H; Cavalli F;
    N Engl J Med; 2015 Mar; 372(10):944-53. PubMed ID: 25738670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma.
    van Keep M; Gairy K; Seshagiri D; Thilakarathne P; Lee D
    BMC Cancer; 2016 Aug; 16(1):598. PubMed ID: 27488675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.
    Drach J; Huang H; Samoilova O; Belch A; Farber C; Bosly A; Novak J; Zaucha J; Dascalescu A; Bunworasate U; Masliak Z; Vilchevskaya K; Robak T; Pei L; Rooney B; van de Velde H; Cavalli F
    Leuk Lymphoma; 2018 Apr; 59(4):896-903. PubMed ID: 29338540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):9-11. PubMed ID: 25768994
    [No Abstract]   [Full Text] [Related]  

  • 7. Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP
    Verhoef G; Robak T; Huang H; Pylypenko H; Siritanaratkul N; Pereira J; Drach J; Mayer J; Okamoto R; Pei L; Rooney B; Cakana A; van de Velde H; Cavalli F
    Haematologica; 2017 May; 102(5):895-902. PubMed ID: 28183846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study
    Robak T; Huang H; Jin J; Zhu J; Liu T; Samoilova O; Pylypenko H; Verhoef G; Siritanaratkul N; Osmanov E; Pereira J; Mayer J; Hong X; Okamoto R; Pei L; Rooney B; van de Velde H; Cavalli F
    Leuk Lymphoma; 2019 Jan; 60(1):172-179. PubMed ID: 28583031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
    J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mantle cell lymphoma: therapeutic options in transplant-ineligible patients.
    Robak T; Smolewski P; Robak P; Dreyling M
    Leuk Lymphoma; 2019 Nov; 60(11):2622-2634. PubMed ID: 31018735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle-cell lymphoma ineligible for intensive therapy: A network meta-analysis.
    Sheng Z; Wang L
    Eur J Haematol; 2023 Jun; 110(6):602-607. PubMed ID: 36919283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma.
    Smith SD; Gandhy S; Gopal AK; Reddy P; Shadman M; Till BG; Lynch RC; Kanan S; Cowan A; Low L; Hill BT
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):48-52. PubMed ID: 30409719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma.
    Furtado M; Johnson R; Kruger A; Turner D; Rule S
    Br J Haematol; 2015 Jan; 168(1):55-62. PubMed ID: 25146720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma.
    Jin J; Okamoto R; Yoon SS; Shih LY; Zhu J; Liu T; Hong X; Pei L; Rooney B; van de Velde H; Huang H
    Onco Targets Ther; 2018; 11():3869-3882. PubMed ID: 30013367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
    J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
    Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
    Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
    Puvvada SD; Guillen-Rodriguez J; Kumar A; Inclán L; Heard K; Rivera XI; Anwer F; Schatz JH; Mahadevan D; Persky DO
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):58-64. PubMed ID: 29056470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.
    Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.
    Chen RW; Palmer JM; Tomassetti S; Popplewell LL; Alluin J; Chomchan P; Nademanee AP; Siddiqi T; Tsai NC; Chen L; Zuo F; Abary R; Cai JL; Herrera AF; Rossi JJ; Rosen ST; Forman SJ; Kwak LW; Holmberg LA
    J Hematol Oncol; 2018 Jun; 11(1):87. PubMed ID: 29954415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.